Clinical Trial: Cell Therapy as Treatment for Cerebral Palsy

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Autologous Bone Marrow Mononuclear Cell Therapy in Cerebral Palsy

Brief Summary: The purpose of this study was to study the effect of autologous bone marrow mononuclear cells on common symptoms of cerebral palsy patients.

Detailed Summary:
Sponsor: Neurogen Brain and Spine Institute

Current Primary Outcome: change in clinical symptoms over a period of 2 years [ Time Frame: 2 years ]

Clinical symptoms such as oromotor skills, sitting and standing balance, speech, ambulation, muscle tone, cognition, hand and leg movement, walking, etc


Original Primary Outcome: change in clinical symptoms over a period of 2 years [ Time Frame: 2 years ]

Current Secondary Outcome:

  • Change in GMFM score [ Time Frame: 1 year ]
  • Change in Gross Motor Function Measure [ Time Frame: 1 year ]


Original Secondary Outcome: Same as current

Information By: Neurogen Brain and Spine Institute

Dates:
Date Received: September 12, 2014
Date Started: August 2013
Date Completion: June 2017
Last Updated: September 23, 2016
Last Verified: September 2016